The 6th-generation Eclipse FFF system handles analytes such as proteins, polymers, viruses, gene vectors, and liposomal drug nanoparticles.
On Oct. 20, 2020, Wyatt Technology, a macromolecular and nanoparticle characterization instrumentation company, launched its 6th-generation Eclipse FFF [field-flow fractionation] system, a new line of separation instrumentation and software for analytes such as proteins, polymers, viruses, gene vectors, and liposomal drug nanoparticles.
The new system covers sizes from 1 nm to 10 μm and supplies programable separation power for improved resolution within any size range, a company press release said. The system also features micro-controllers and sensors with built-in intelligence for easy use in quality control environments.
Additionally, the new system comes enabled with Mobility for electrical/asymmetric-flow FFF for determining size-resolved zeta potential, and a Dilution Control Module to increase sample concentrations for higher sensitivity and fraction titer, the press release said.
“The complete execution of a product redesign is difficult enough under ordinary circumstances, but in this case it was re-imagining of what FFF is and how it can be made more accessible to more scientists,” said Geofrey Wyatt, CEO of Wyatt Technology, in the press release. “The resulting products, their novelty and their utility move FFF from a relatively obscure area of separation science into the mainstream.”
Source: Wyatt
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.